EMA advises on gathering patient feedback for oncology medicines
Advises on how patient-reported outcome data should be integrated in oncology clinical trials
The European Medicines Agency (EMA) has published new guidance on using patient-reported outcome (PRO) measures in oncology studies. It outlines principles of scientific best practice rather than prescribing particular approaches to selecting and using PROs and advises on how patient-reported outcome data should be integrated in oncology clinical trials.